A UCL-led study reports that long-acting antiretroviral injections given every eight weeks help adolescents living with HIV maintain viral suppression more effectively than daily oral tablets. The findings are published in *The Lancet* and compare an injection-based regimen with standard daily pill treatment.
Both outlets describe the study as focusing on young people and measuring outcomes related to keeping the virus suppressed over time. Researchers conclude that the eight-week dosing approach may improve treatment effectiveness and adherence-related outcomes compared with daily dosing. The coverage highlights the study’s call for further attention to long-acting formulations for adolescents as health systems consider options beyond daily pills.
While the articles share the same core results and publication venue, they present the same message through slightly different wording: *The Zimbabwe Independent* emphasizes improved management of HIV with eight-week injections, while *New Zimbabwe* stresses the greater effectiveness of injections for sustaining viral suppression and the need to consider such regimens more broadly for adolescents.
